Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
SAN DIEGO, Feb. 18, 2016 -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced that George Mahaffey offered his resignation as Chief Executive Officer and Chairman of the Board, effective immediately. The board has formed a committee to oversee day to day operations until a replacement is found. The Company also announced it is evaluating a path forward with a modified formulation of its lead asset LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat. Neothetics will provide a more detailed update in its 10-K and 4Q2015 release.
Neothetics today also reported preliminary fourth quarter 2015 cash and cash equivalents as of December 31, 2015 of approximately $37.7 million.
To receive Neothetics' press releases and other investor information, please go to the Investor Relations page of the company's website at investors.neothetics.com and register for email alerts.
About Neothetics, Inc.
Neothetics is a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market. The lead product candidate, LIPO-202, is for central abdominal bulging due to subcutaneous fat in non-obese subjects, an indication for which there is no FDA-approved drug. If approved, LIPO-202 may be a best-in-class non-surgical, non-ablative procedure and first-in-class injectable formulation for localized fat reduction and body contouring. For more information on Neothetics, please visit www.neothetics.com. Neothetics, LIPO-202, LIPO-102 and the Neothetics logo are trademarks or registered trademarks of Neothetics, Inc. Other names and brands may be claimed as the property of others.
COMPANY CONTACTS: Susan A. Knudson Chief Financial Officer 858-500-7780 [email protected] Fara Berkowitz, R.Ph, Pharm.D Senior Director, Investor Relations and Corporate Strategy 917-460-9307 [email protected]
